SouthState Corp Has $8.91 Million Holdings in Boston Scientific Co. (NYSE:BSX)

SouthState Corp raised its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 154,095 shares of the medical equipment provider’s stock after buying an additional 973 shares during the period. SouthState Corp’s holdings in Boston Scientific were worth $8,908,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Running Oak Capital LLC lifted its stake in Boston Scientific by 17.7% in the fourth quarter. Running Oak Capital LLC now owns 153,875 shares of the medical equipment provider’s stock valued at $8,896,000 after buying an additional 23,091 shares during the period. Aveo Capital Partners LLC lifted its holdings in Boston Scientific by 1.3% in the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock worth $742,000 after buying an additional 171 shares during the period. First Horizon Advisors Inc. raised its stake in Boston Scientific by 7.7% during the fourth quarter. First Horizon Advisors Inc. now owns 4,970 shares of the medical equipment provider’s stock valued at $287,000 after buying an additional 356 shares during the last quarter. West Family Investments Inc. grew its holdings in shares of Boston Scientific by 12.2% in the fourth quarter. West Family Investments Inc. now owns 4,354 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 473 shares during the period. Finally, Fisher Asset Management LLC grew its holdings in Boston Scientific by 0.6% during the fourth quarter. Fisher Asset Management LLC now owns 3,993,388 shares of the medical equipment provider’s stock valued at $230,858,000 after purchasing an additional 22,946 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Citigroup raised their price objective on Boston Scientific from $79.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Royal Bank of Canada increased their target price on Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Argus increased their target price on Boston Scientific from $69.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Robert W. Baird increased their target price on Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.09.

Insiders Place Their Bets

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total value of $899,779.32. Following the completion of the sale, the chief financial officer now owns 271,542 shares in the company, valued at approximately $17,883,756.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,797 shares of company stock valued at $4,138,090. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Down 0.2 %

Shares of Boston Scientific stock traded down $0.18 during trading hours on Thursday, reaching $72.03. 6,487,185 shares of the company’s stock were exchanged, compared to its average volume of 6,639,147. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $74.39. The firm has a market capitalization of $108.05 billion, a price-to-earnings ratio of 60.68, a price-to-earnings-growth ratio of 2.47 and a beta of 0.77. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average of $68.20 and a 200-day moving average of $61.03.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. During the same quarter last year, the business earned $0.45 earnings per share. Sell-side analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.